AKT1 and neoplasm: Selumetinib combined with AKT inhibitor MK2206 showed synergistic effect in GNAQ-mutant UM cell lines and decreased tumor growth in xenograft mouse models [31] however in a phase 2 clinical trial, efficacy of trametinib with or without AKT inhibitor GSK2141795 failed to show any survival benefit with no difference in PFS, and only one PR was observed with ORR of 5% [32].